|
A new report from BioWorld Today...
BioWorld®China Biotech 2009
Go here for details on this report.
BioWorld's China Biotech 2009 provides an unprecedented look at new developments in biotechnology in China. How can outside firms tap into the exploding research pipeline in China? What about the Heparin scare? Where are the best opportunities for investment?
With China Biotech 2009, you will receive answers and information on the following current events and industry trends:
Access to capital: Sources of funding/investment trends in the Chinese biotech sector.
Intellectual property: Impact of the new amendment to China's patent law.
Recent MNC moves: China activities of the larger biotech companies as well as Big Pharma.
Outsourcing update: Latest on the rapidly growing and expanding outsourcing sector.
Shocks to the market: Wenchuan earthquake, the Heparin recall and the Olympics.
Industry trends: Profiles of biofuels, stem cells, biologics/biosimilars, and more.
Key financial metrics are also provided in China Biotech 2009 on the commercial side of the industry. Access to hard-to-get investment information is available, as well as trend analysis of various sectors and companies. Highlights of these table-focused sections include:
-
Overseas IPO Results Involving Chinese Bio Companies
-
VC Investments in China's Biotech and Pharma Industries
-
Major Joint Venture/Wholly Foreign-Owned Enterprises in China
-
China's Clinical Phase Pipeline Grouped by Innovation Class
-
Sector Information on Biologics, Antibodies, Vaccines, Diagnostics, Agricultural Biotech and Biofuels.
People who need this report include:
-
Biotechnology and pharmaceutical executives
-
Medical device and technology company executives
-
Healthcare IT companies
-
Analysts and investors
-
Research and development directors
-
Technology transfer officers
-
Local and state governments
-
Attorneys
More Information Online:
View more details on this report here. Or call us at 1-800-688-2421 or 1-404-262-5476 and mention priority code S08432-EM/6499.
|
